{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:42:50Z","timestamp":1786189370107,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08669-y","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:04:24Z","timestamp":1784631864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-Driven discovery and experimental validation of covalent FGFR4 inhibitors for hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Mingjie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"3","key":"8669_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clinicians"},{"issue":"3","key":"8669_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. WIREs Dev Biol. 2015;4(3):215\u201366. https:\/\/doi.org\/10.1002\/wdev.176.","journal-title":"WIREs Dev Biol"},{"issue":"5","key":"8669_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mco2.367","volume":"4","author":"Q Liu","year":"2023","unstructured":"Liu Q, Huang J, Yan W, Liu Z, Liu S, Fang W. Fgfr families: biological functions and therapeutic interventions in tumors. MedComm. 2023;4(5):367. https:\/\/doi.org\/10.1002\/mco2.367.","journal-title":"MedComm"},{"issue":"8","key":"8669_CR4","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. Azd4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3034.","journal-title":"Cancer Res"},{"issue":"16","key":"8669_CR5","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","volume":"25","author":"R Bahleda","year":"2019","unstructured":"Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, et al. Multicenter phase i study of erdafitinib (jnj-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25(16):4888\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3334.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"8669_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park J-W, et al. First-in-human phase i study of fisogatinib (blu-554) validates aberrant fgf19 signaling as a driver event in hepatocellular carcinoma. Cancer DiscovCancer Discov. 2019;9(12):1696\u2013707. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0555.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"24","key":"8669_CR7","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","volume":"77","author":"JJ Joshi","year":"2017","unstructured":"Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang C-L, Ichikawa K, et al. H3b-6527 is a potent and selective inhibitor of fgfr4 in fgf19-driven hepatocellular carcinoma. Cancer Res. 2017;77(24):6999\u20137013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1865.","journal-title":"Cancer Res"},{"issue":"21","key":"8669_CR8","doi-asserted-by":"publisher","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","volume":"63","author":"RA Fairhurst","year":"2020","unstructured":"Fairhurst RA, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, et al. Discovery of roblitinib (fgf401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4. J Med Chem. 2020;63(21):12542\u201373. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01019.","journal-title":"J Med Chem"},{"issue":"12","key":"8669_CR9","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","volume":"18","author":"A Weiss","year":"2019","unstructured":"Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, et al. Fgf401, a first-in-class highly selective and potent fgfr4 inhibitor for the treatment of fgf19-driven hepatocellular cancer. Mol Cancer Ther. 2019;18(12):2194\u2013206. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1291.","journal-title":"Mol Cancer Ther"},{"issue":"45","key":"8669_CR10","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1073\/pnas.1403438111","volume":"111","author":"L Tan","year":"2014","unstructured":"Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, et al. Development of covalent inhibitors that can overcome resistance to first-generation fgfr kinase inhibitors. Proc Natl Acad Sci USA. 2014;111(45):4869\u201377. https:\/\/doi.org\/10.1073\/pnas.1403438111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"8669_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","volume":"14","author":"S Ito","year":"2023","unstructured":"Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, et al. Discovery of futibatinib: the first covalent fgfr kinase inhibitor in clinical use. ACS Med Chem Lett. 2023;14(4):396\u2013404. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00006.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"8669_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s42004-022-00657-9","volume":"5","author":"X Chen","year":"2022","unstructured":"Chen X, Li H, Lin Q, Dai S, Yue S, Qu L, et al. Structure-based design of a dual-warhead covalent inhibitor of fgfr4. Commun Chem. 2022;5(1):36. https:\/\/doi.org\/10.1038\/s42004-022-00657-9.","journal-title":"Commun Chem"},{"issue":"12","key":"8669_CR13","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1039\/D2MD00216G","volume":"13","author":"C Gai","year":"2022","unstructured":"Gai C, Harnor SJ, Zhang S, Cano C, Zhuang C, Zhao Q. Advanced approaches of developing targeted covalent drugs. RSC Med Chem. 2022;13(12):1460\u201375. https:\/\/doi.org\/10.1039\/D2MD00216G.","journal-title":"RSC Med Chem"},{"key":"8669_CR14","doi-asserted-by":"publisher","unstructured":"Zeng Q, Hu H, Huang Z, Guo A, Lu S, Tong W, et al. Active and machine learning-enhanced discovery of new fgfr3 inhibitor, rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment. Front Mol Biosci. 2024;11, 1413214 (https:\/\/doi.org\/10.3389\/fmolb.2024.1413214.","DOI":"10.3389\/fmolb.2024.1413214"},{"issue":"2","key":"8669_CR15","doi-asserted-by":"publisher","first-page":"081","DOI":"10.1093\/bib\/bbae081","volume":"25","author":"H Wang","year":"2024","unstructured":"Wang H. Prediction of protein\u2013ligand binding affinity via deep learning models. Briefings Bioinf. 2024;25(2):081. https:\/\/doi.org\/10.1093\/bib\/bbae081.","journal-title":"Briefings Bioinf"},{"issue":"10","key":"8669_CR16","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1021\/acs.jmedchem.5c00512","volume":"68","author":"EG Garc\u00eda","year":"2025","unstructured":"Garc\u00eda EG, Varas P, Gonz\u00e1lez-Naranjo P, Ulzurrun E, Marcos-Ayuso G, P\u00e9rez C, et al. Ai-driven de novo design and development of nontoxic dyrk1a inhibitors. J Med Chem. 2025;68(10):10346\u201364. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00512.","journal-title":"J Med Chem"},{"issue":"3","key":"8669_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41596-021-00659-2","volume":"17","author":"F Gentile","year":"2022","unstructured":"Gentile F, Yaacoub JC, Gleave J, Fernandez M, Ton A-T, Ban F, et al. Artificial intelligence\u2013enabled virtual screening of ultra-large chemical libraries with deep docking. Nat Protoc. 2022;17(3):672\u201397. https:\/\/doi.org\/10.1038\/s41596-021-00659-2.","journal-title":"Nat Protoc"},{"issue":"1","key":"8669_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10822-024-00560-6","volume":"38","author":"AD Danilack","year":"2024","unstructured":"Danilack AD, Dickson CJ, Soylu C, Fortunato M, Rodde S, Munkler H, et al. Reactivities of acrylamide warheads toward cysteine targets: a qm\/ml approach to covalent inhibitor design. J Comput Aided Mol Des. 2024;38(1):21. https:\/\/doi.org\/10.1007\/s10822-024-00560-6.","journal-title":"J Comput Aided Mol Des"},{"key":"8669_CR19","doi-asserted-by":"publisher","unstructured":"Du H, Zhang X, Wu Z, Zhang O, Gu S, Wang M, et al. Covalentindb 2.0: an updated comprehensive database for structure-based and ligand-based covalent inhibitor design and screening. Nucleic Acids Res. 2025;53(D1):D1322\u201327. https:\/\/doi.org\/10.1093\/nar\/gkae946.","DOI":"10.1093\/nar\/gkae946"},{"key":"8669_CR20","doi-asserted-by":"publisher","unstructured":"Gao M, Moumbock AFA, Qaseem A, Xu Q, G\u00fcnther S. Covpdb: a high-resolution coverage of the covalent protein\u2013ligand interactome. Nucleic Acids Res. 2022;50(D1):D445\u201350. https:\/\/doi.org\/10.1093\/nar\/gkab868.","DOI":"10.1093\/nar\/gkab868"},{"issue":"1","key":"8669_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1021\/acs.jcim.3c01250","volume":"64","author":"E Heid","year":"2024","unstructured":"Heid E, Greenman KP, Chung Y, Li S-C, Graff DE, Vermeire FH, et al. Chemprop: a machine learning package for chemical property prediction. J Chem Inf Model. 2024;64(1):9\u201317. https:\/\/doi.org\/10.1021\/acs.jcim.3c01250.","journal-title":"J Chem Inf Model"},{"issue":"8","key":"8669_CR22","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1021\/acs.jcim.9b00237","volume":"59","author":"K Yang","year":"2019","unstructured":"Yang K, Swanson K, Jin W, Coley C, Eiden P, Gao H, et al. Analyzing learned molecular representations for property prediction. J Chem Inf Model. 2019;59(8):3370\u201388. https:\/\/doi.org\/10.1021\/acs.jcim.9b00237.","journal-title":"J Chem Inf Model"},{"issue":"8","key":"8669_CR23","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1021\/acs.jcim.9b00316","volume":"59","author":"F Palazzesi","year":"2019","unstructured":"Palazzesi F, Grundl MA, Pautsch A, Weber A, Tautermann, Tautermann CS. C.S.: a fast ab initio predictor tool for covalent reactivity estimation of acrylamides. J Chem Inf Model. 2019;59(8):3565\u201371. https:\/\/doi.org\/10.1021\/acs.jcim.9b00316.","journal-title":"J Chem Inf Model"},{"key":"8669_CR24","doi-asserted-by":"publisher","unstructured":"Chattaraj PK, Roy DR. Update 1 of: electrophilicity index. Chem Rev. 2007;107(9):PR46\u201374. https:\/\/doi.org\/10.1021\/cr078014b.","DOI":"10.1021\/cr078014b"},{"issue":"6","key":"8669_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/molecules21060748","volume":"21","author":"LR Domingo","year":"2016","unstructured":"Domingo LR, R\u00edos-Guti\u00e9rrez M, P\u00e9rez P. Applications of the conceptual density functional theory indices to organic chemistry reactivity. Molecules. 2016;21(6):748. https:\/\/doi.org\/10.3390\/molecules21060748.","journal-title":"Molecules"},{"issue":"42","key":"8669_CR26","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1039\/C9CC02052G","volume":"55","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Chen X, Fu Y, Zhang Y, Dai S, Li J, Chen L, Xu G, Chen Z, Chen Y. Characterization of fgf401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. Chem Commun. 2019;55(42):5890\u201393. https:\/\/doi.org\/10.1039\/C9CC02052G.","journal-title":"Chem Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08669-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T10:54:08Z","timestamp":1786186448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08669-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8669"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08669-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1020"}}